Dolutegravir/lamivudine/tenofovir disoproxil fumarate - Aurobindo Pharma

Drug Profile

Dolutegravir/lamivudine/tenofovir disoproxil fumarate - Aurobindo Pharma

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aurobindo Pharma
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Oxazines; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

  • 05 Oct 2017 Chemical structure information added
  • 21 Aug 2017 Aurobindo Pharma intends to launch dolutegravir/lamivudine/tenofovir disoproxil fumarate tablets in sub-Saharan Africa in 2018
  • 21 Aug 2017 FDA issues tentative approval to dolutegravir/lamivudine/tenofovir disoproxil fumarate (50 mg/300 mg/300 mg) tablets for the treatment of HIV-1 infections (In adults, In adolescents) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top